Lower urinary tract symptoms · 2025
Efficacy and Safety of Thulium Laser Vaporization of the Prostate: A Transurethral Procedure for Benign Prostatic Hyperplasia.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gotoh Daisuke, Torimoto Kazumasa, Tachibana Akira, Nishimura Nobutaka, Tomizawa Mitsuru, Onishi Kenta, Morizawa Yosuke, Hori Shunta, Nakai Yasushi, Miyake Makito, Fujimoto Kiyohide
Аннотация
OBJECTIVES: To explore the efficacy and safety of thulium laser vaporization of the prostate (ThuVAP) for benign prostatic hyperplasia (BPH) at Nara Medical University from 2022 to 2024.
METHODS: Patients with BPH who underwent ThuVAP at the Department of Urology, Nara Medical University, between January 01, 2022 and April 30, 2024, were enrolled. Patient background, presurgical pressure flow study results, treatment efficacy, and safety were retrospectively evaluated.
RESULTS: The study included 32 patients; the median age was 74.5 years at surgery. The total International Prostate Symptom Score and quality of life were significantly lower at 4 weeks after surgery than at baseline. They continued to decrease at 12 and 24 weeks. The maximum flow rate was significantly higher at 4 weeks after surgery than at baseline; it continued to increase for 12 and 24 weeks. The postvoid residual (PVR) was significantly lower at 4 weeks after surgery than at baseline and continued to decrease at 12 and 24 weeks. Intravesical prostatic protrusion and prostate volume were positively correlated with the surgery and laser usage times. Two patients experienced temporary urinary retention, and two underwent transurethral electrocoagulation for postoperative bleeding.
CONCLUSIONS: Our data confirm ThuVAP as an effective and safe treatment for BPH.
METHODS: Patients with BPH who underwent ThuVAP at the Department of Urology, Nara Medical University, between January 01, 2022 and April 30, 2024, were enrolled. Patient background, presurgical pressure flow study results, treatment efficacy, and safety were retrospectively evaluated.
RESULTS: The study included 32 patients; the median age was 74.5 years at surgery. The total International Prostate Symptom Score and quality of life were significantly lower at 4 weeks after surgery than at baseline. They continued to decrease at 12 and 24 weeks. The maximum flow rate was significantly higher at 4 weeks after surgery than at baseline; it continued to increase for 12 and 24 weeks. The postvoid residual (PVR) was significantly lower at 4 weeks after surgery than at baseline and continued to decrease at 12 and 24 weeks. Intravesical prostatic protrusion and prostate volume were positively correlated with the surgery and laser usage times. Two patients experienced temporary urinary retention, and two underwent transurethral electrocoagulation for postoperative bleeding.
CONCLUSIONS: Our data confirm ThuVAP as an effective and safe treatment for BPH.